Table 2.
Multiple linear regression with urinary albumin excretion regarding other parameters at 8 weeks.
| CKD stage | Characteristic | β | t value | P value | Adjusted R2 | F value | P value |
|---|---|---|---|---|---|---|---|
| Model 1 | Plasma phosphate | 0.32 | 4.25 | <0.001 | 0.45 | 18.0 | <0.001 |
| Model 2 | Plasma phosphate CCr |
0.31 | 5.93 | <0.001 | 0.73 | 30.1 | <0.001 |
| −2.52 | −4.72 | <0.001 | |||||
| Model 3 | Plasma phosphate CCr Urine phosphate |
0.05 | 0.43 | 0.67 | 0.80 | 28.5 | <0.001 |
| −3.55 | −5.84 | <0.001 | |||||
| 0.30 | 2.63 | 0.017 | |||||
| Model 4 | CCr Urine phosphate |
−3.71 | −7.81 | <0.001 | 0.81 | 44.6 | <0.001 |
| 0.35 | 7.43 | <0.001 |
Multiple linear regression analysis for urinary albumin excretion was performed in an incremental inclusion manner using other independent parameters at 8 weeks including body weight, blood pressure, CCr, urinary phosphate, plasma phosphate, plasma FGF23, plasma intact PTH, plasma 1,25(OH)2 vitamin D and plasma CPP. Urinary excretion of albumin and phosphate and plasma levels of FGF23, intact PTH, 1,25(OH)2 vitamin D and CPP were log-transformed prior to the analysis. Abbreviations. CCr: creatinine clearance corrected for body weight of 100 g; FGF23, fibroblast growth factor 23; CPP, calciprotein particle.